COMPARATIVE EFFICACY AND SAFETY OF INHALED INDACATEROL AND TIOTROPIUM IN GOLD STAGE-2 PATIENTS OF COPD
DOI:
https://doi.org/10.22270/ijmspr.v1i3.9Keywords:
COPD, Tiotropium, Indacaterol, GOLDAbstract
Background:Current treatment guidelines, such as those from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) describe bronchodilators as the first-line therapy for patients with moderate to very severe COPD (stage 2-4 of GOLD Spirometric Criteria for COPD Severity). Indacaterol is a new once daily inhaled bronchodilator, recently approved for the treatment of COPD. Once daily dosing is an important step to improve the adherence and compliance of the patients. Methods: In this prospective, parallel group and open labelled study we compared Efficacy and Safety of Indacaerol and Tiotropium in Patients of Satge-2 GOLD. Total 60 patients were finally evaluated in the study. They were divided in two groups, group-1 (Indacaterol group) and group-2 (Tiotropium group) receiving 150 mcg/daily of Indacaterol and 18 mcg/daily of Tiotropium in each group respectively. All patients were evaluated by measuring FEV1 at zero day (before therapeutic intervention), 2, 4, 6, 8, 10 and 12 weeks. Results: Patients in both group showed gradual improvement at 2, 4, 6, 8, 10 and 12 weeks, but there was better improvement in Tiotropium as compared to Indacaterol group in terms of FEV1 . Although this difference was not statistically significant. Conclusion: Indacaterol 150 mcg/day is equally effective as Tiotropium in dose of 18 mcg /day patients of moderate COPD (stage-2 GOLD criteria).
References
Buhl R, Dunn LJ, Disdier C, et al. (2011), “INTENSITY Study Group. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD”, EurRespir J., Vol. 38, pp. 797–803.
Buist A S, McBurnie M A, Vollmer W M, et al. (2007), “International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study”, Lancet , Vol. 370, pp. 741–750.
Buhl R, Dunn L J, Disdier C, Lassen C, Amos C, Henley M and Kramer B (2011), EurRespir J., Vol. 38, pp. 797–803.
Cazzola M, Page C P, Calzetta L, et al. (2012), “Pharmacology and therapeutics of bronchodilators”, Pharmacol Rev., Vol. 64, pp. 450-504.
Claus Vogelmeier, David Ramos Barbon, Damon Jack, Simon Piggott, Roger Owen, Mark Higgins, Benjamin Kramer (2011), “INTIME study investigators (INdacaterol & TIotropium: Measuring Efficacy)”, Respiratory Research, Vol. 11:135 doi:10.1186/1465-9921-11-135
Dahl R, Chung K F, Buhl R, et al. (2010), “INVOLVE (Indacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily long-acting inhaled b2- agonist indacaterol versus twice-daily formoterol in COPD”, Thorax, Vol. 65, pp. 473-9.
Donald A Mahler, Anthony D’Urzo Eric D Bateman, Serir A O¨zkan, Tracy White, Clare Peckitt,Cheryl Lassen, Benjamin Kramer (2012), “Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison Chronic obstructive pulmonary disease”, pp. 5-8, doi:10.1136/thoraxjnl-2011-201140
Donohue J F, Fogarty C, Lotvall J, et al. (2010), “INHANCE study investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium”, Am J RespirCrit Care Med., Vol. 182, pp. 155–162.
Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD. 2010. www.goldcopd.org.
Gustavo J Rodrigo and Hugo Neffen (2012), A systematic review CHEST, Vol. 142, No. 5, pp. 1104–1110.
Halbert R J, Natoli J L, Gano A, Badamgarav E, Buist A S, Mannino D M (2006), “Global burden of COPD: systematic review and meta-analysis”, Eur Respir J, Vol. 28 No. 3, pp. 523–532.
Hanania N A and Marciniuk D D (2011), “A unified front against COPD: clinical practice guidelines from the American College of Physicians, the American College of Chest Physicians, the American Thoracic Society, and the European Society”, Chest, Vol. 140, No. 3, pp. 565–566.
Kornmann O, Dahl R, Centanni S, et al. (2011), “INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-mg Doses with COPD Patients) Study Investigators. Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison”, Eur Respir J., Vol. 37, pp. 273-9.
Mannino D M and Buist A S (2007), “Global burden of COPD: risk factors, prevalence, and future trends”, Lancet, Vol. 370, pp. 765– 773.
O’Reilly J, Jones M M, Parnham J, et al. (2010), “Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance”, BMJ, Vol. 340, pp. c3134.
Pascoe S, Reynolds C, Pleskow W, et al. (2011), “Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily beta2- agonist bronchodilator, in subjects with COPD”, Int J ClinPharmacol Ther., Vol. 49, pp. 153–16.
Rodrigo G Jand Nannini L J (2007), “Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis”, Pulm Pharmacol Ther., Vol. 20, No. 5, pp. 495- 502.
Stephanie Korn , Edward Kerwin, SibelAtis, Carolynn Amos, Roger Owen (2011), Cheryl Lassen Respiratory Medicine, Vol. 105, pp. 719-726.
Tashkin D P, Celli B, Senn S, et al. (2008), “A 4-year trial of tiotropium in chronic obstructive pulmonary disease”, N Engl J Med., Vol. 359, pp. 1543-54.
Vogelmeier C, Magnussen H, LaForce C, Owen R, Kramer B (2011), “Profiling the bronchodilator effects of the novel ultra-long acting b2-agonist inda-caterol against established treatments in chronic obstructive pulmonary disease”, Ther Adv Respir Dis., Vol. 5, pp. 345–357.
Vogelmeier C, Ramos-Barbon D, Jack D, Piggott S, Owen R, Higgins M (2010), “INTIME Study Investigators. Indacaterol provides 24-hour bronchodila-tion in COPD: a placebo-controlled blinded comparison with tiotropium”, Respir Res., Vol. 11, pp. 135–139
Published
How to Cite
Issue
Section
Copyright (c) 2015 Admin ijmspr
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
.